Namaste! Main ek Professional Equity Research Analyst hoon. Aaj (22 February 2026) tak ke latest internet data, market price aur recent financial results ke aadhar par maine Procter & Gamble Health Ltd. (PGHL) ka ek deep fundamental analysis taiyar kiya hai.
Maine strictly primary sources (Screener.in aur Yahoo Finance) ka use kiya hai. Jahan data points me mismatch mila hai, wahan maine dono ko mention karke clearly “DATA SOURCE DIFFERENCE OBSERVED” likha hai.
Yeh rahi aapki structured equity research report:
1️⃣ Business Model & Work
- Company exactly kya kaam karti hai? Procter & Gamble Health (pehle Merck Ltd. ke naam se jani jati thi) India ki ek leading VMS (Vitamins, Minerals, and Supplements) company hai. Yeh over-the-counter (OTC) supplements aur pharma products banati aur market karti hai.
- Main Brands & Revenue Source: Inke strong legacy brands me Neurobion, Polybion, Evion (Vitamins), Livogen (Iron supplement), Nasivion (Nasal decongestant), aur SevenSeas shamil hain.
- Domestic vs Export exposure: Revenue ka major hissa domestic Indian market se aata hai, halanki exports bhi inke revenue model ka ek hissa hain (approximate exact split current data me DATA NOT AVAILABLE).
- Competitive Advantage: Strong MNC parentage (P&G Group), doctor-recommended legacy brands, aur high consumer trust inka sabse bada economic moat hai.
2️⃣ Industry & Sector Analysis
- Sector ka current status: Healthcare aur Pharmaceuticals (VMS specifically). Post-COVID, daily supplements aur preventative healthcare ko lekar logo me kafi awareness aayi hai.
- Cyclical ya Secular? Yeh puri tarah se Secular sector hai. Economic slowdown aane par bhi log basic healthcare, vitamins aur iron supplements lena band nahi karte.
- Growth Drivers: India ki middle-class ka rising disposable income, lifestyle diseases me badhotri, aur consumer health awareness is industry ke main growth pillars hain.
- Major Competitors: Zydus Lifesciences, Sun Pharma, Dr. Reddy’s Labs, Lupin, Abbott India, aur Sanofi India.
3️⃣ Latest Financial Performance (STRICT DATA RULE)
Company July-June financial year follow karti hai.
| Period (FY / Quarter) | Revenue (₹ Cr) | Net Profit (PAT) (₹ Cr) | Operating / EBITDA Margin |
| FY21 (Ended Jun 2021) | 1,008.73 | 176.80 | ~24.39% |
| FY22 (Ended Jun 2022) | 1,114.41 | 192.52 | ~24.02% |
| FY23 (Ended Jun 2023) | 1,229.62 | 229.47 | ~26.40% |
| FY24 (Ended Jun 2024) | 1,151.26 | 200.98 | ~24.83% |
| Latest Qtr (Dec 2025) | 373.86* | 77.59 | ~29.13% |
(⚠️ DATA SOURCE DIFFERENCE OBSERVED: Latest Dec 2025 quarter ke revenue ke liye Screener ₹373.86 Cr dikha raha hai, jabki Yahoo Finance/INDmoney ₹378.22 Cr report kar raha hai. Net profit dono jagah lagbhag ₹77.59 Cr hai, jo pichle saal ke same quarter ke mukable ~14.64% gira hai.)
- ROE (Return on Equity): 32.74% – 36.4% (Excellent historical trend)
- ROCE (Return on Capital Employed): 39.76% – 47.8% (Highly capital efficient)
- Debt/Equity: 0.01 – 0.02 (Company practically Debt-Free hai).
- Free Cash Flow: P&G MNC hone ke nate cash generation bahut strong hai aur working capital well-managed hai.
4️⃣ Management & Shareholding (Latest Only)
- Promoter Holding: 51.8% (Procter & Gamble Overseas India B.V. ke paas). Pledged shares: 0%.
- Institutional Holding (FII/DII): DIIs (Mutual Funds) ka accha conviction hai. Nippon Life India (~4.2%), ICICI Prudential (~2.8%), aur UTI MNC Fund (~1.9%) major holders hain. FII/DII trend overall stable hai.
- Management Track Record & Governance: Management clean hai. P&G group ki strict corporate governance policies apply hoti hain. Company consistently high dividend payout maintain karti hai (upcoming dividend ₹110 per share announce hua hai).
5️⃣ Valuation (Latest Market Data Only)
Current Market Price (CMP): ~ ₹5,019.50
- P/E Ratio: ⚠️ DATA SOURCE DIFFERENCE OBSERVED (Screener par P/E 36.41 hai, jabki Yahoo Finance par 28.39 hai).
- P/B Ratio: ~13.4 se 15.57.
- EV/EBITDA: ~25.42.
- Dividend Yield: 2.49% (Screener) se 5.68% (Yahoo Finance). DATA SOURCE DIFFERENCE OBSERVED.
- Peer Comparison: Apne pharma peers (Sun Pharma, Zydus) ke mukable PGHL ek MNC premium enjoy karti hai (due to ~40%+ ROCE and strong brands), lekin slow topline growth ki wajah se current valuation thoda stretched lagta hai.
- Fair Value Approach: Slow historical sales growth (last 5 years me virtually flat ~0.16% CAGR) ko dekhte hue relative valuation ke hisaab se stock abhi fair-to-slightly-overvalued range me trade kar raha hai. (DCF cannot be run confidently bina future growth estimates ke).
6️⃣ Future Growth Triggers (3–5 Years)
- Brand Premiumisation: Company apne core VMS brands (Neurobion, Evion) me naye variants (jaise injection lines ya premium packs) launch karke margin improve kar rahi hai.
- Industry Tailwinds: India me preventive healthcare aur daily supplementation ka market double-digit rate se grow kar raha hai.
- Parent Support: P&G group apni global supply chain, R&D aur distribution network ke through PGHL ka reach rural India tak badhane par focus kar raha hai.
7️⃣ Present Situation (Current Outlook)
- Stock ka Current Phase: Stock abhi consolidation/correction phase me hai (last 1 year return approx -6.1% hai). Technical basis par ₹4,900 ke aas-paas strong support aur ₹5,200 par resistance dikh raha hai.
- Recent Developments: Dec 2025 ke latest quarter me revenue 20%+ YoY badha, lekin net profit me ~14.6% ki girawat aayi (margins contract hue hain shayad input costs ya operational expenses badhne se). Is mixed result ne stock ko range-bound rakha hai.
- Short-term Outlook: Volatile rahne ki ummeed hai kyunki latest quarter me profit dip hua hai.
- Long-term Outlook: Fundamental strength (Zero debt, high ROE/ROCE, stable brands) long term ke liye intact hai.
8️⃣ Risk & Red Flags
- Business/Financial Risks: Pichle 5 saalo me Top-line (Sales) growth almost zero (0.16% CAGR) rahi hai. Ek growth company ke bina, high P/E (36x) sustain karna mushkil hota hai.
- Industry Headwinds: VMS (Vitamins) space me competition bahut tezi se badh raha hai. Na sirf traditional pharma, balki FMCG aur D2C nutraceutical brands market share kha rahe hain.
- Governance / Litigation: Koi major confirmed governance red flags NAHI hain. MNC management completely transparent hai.
9️⃣ Final Verdict
- PGHL ek fundamentally rock-solid, zero-debt, aur exceptionally high ROCE (~47%) wali MNC company hai.
- Iske legacy brands (Evion, Neurobion) par consumer aur doctor ka heavy trust hai.
- Conservative Investor Suitability: High dividend yield aur low volatility ke karan FD se behtar, safe wealth preservation ke liye yeh stock suitable hai. Isme down-side risk kam hai.
- Aggressive Investor Suitability: Growth ki kami (low sales CAGR) ke karan yeh stock multi-bagger returns nahi dega. Aggressive investors ise avoid kar sakte hain.
- Approximate Target Range & Risk-Reward: Agar company double-digit sales growth wapas lati hai (assumption), to stock easily apna all-time high (₹6,700+) touch kar sakta hai. Risk-reward filhal neutral-to-favourable hai un logo ke liye jinhe dividend se regular passive income chahiye.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pahle apne Financial Advisor se salah zarur lein.